Sandoz and mAbxience agree on emicizumab biosimilar partnership
Sandoz and mAbxience have signed a licensing, development and commercialisation agreement for a proposed emicizumab biosimilar candidate for haemophilia A.
Read the full article on the original site.
Read Full Article